In this phase III trial, patients with malignant pleural mesothelioma that has progressed despite platinum-based treatment receive either immunotherapy with pembrolizumab or standard chemotherapy (gemcitabine or vinorelbine). The primary endpoint of the study is progression-free survival.
Data from the study was presented at the ESMO 2019 Congress showing that it had failed to meet its primary endpoint.
Sanjay Popat reports on the PROMISE-meso trial and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53):